Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Breast Cancer | Research

Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan

Authors: Esmatullah Esmat, Ahmed Maseh Haidary, Ramin Saadaat, Syeda Naghma Rizvi, Syeda Aleena, Mujtaba Haidari, Sayed Murtaza Sadat Hofiani, Nasrin Hussaini, Ahmadullah Hakimi, Abdullatif Khairy, Jamshid Abdul-Ghafar

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Breast cancer (BC) is one of the major causes of death worldwide. It is the most common cause of death before the age of 70 years. The incidence and mortality of BC are rapidly increasing, posing great challenges to the health system and economy of every nation.

Methodology

A cross-sectional analytical study was conducted at the Department of Pathology and Clinical Laboratory of the French Medical Institute for Mothers and Children (FMIC) to demonstrate the association of human epidermal growth factor receptor 2 (Her2/Neu) and estrogen receptor (ER)/ progesterone receptor (PR) with clinical as well as pathological parameters among women with BC. A consecutive nonprobability sampling method was used for this study over a span of one and a half years.

Results

One hundred twenty participants diagnosed with breast cancer were included in the study. The mean age at diagnosis was 44.58 ± 11.16 years. Out of the total patients, 68 (56.7%) were above 40 years old, 108 (90%) were married, 94 (78.3%) were multiparous, and 88 (73.3%) had a history of breastfeeding. 33.3% of cases were within the age range of menopause (40–50 years). The positive expression rates of ER, PR, and Her2/neu were found to be 48.8%, 44.6%, and 44.6%, respectively, and Her2/neu overexpression was found to be higher among ER/PR-negative cases.

Conclusion

In our study, we demonstrated that among Afghan women, grade II invasive ductal carcinoma, not otherwise specified, was the most common type of BC and frequently affected women above the age of 40. We also revealed that the percentage of negative ER (50.4%), negative PR (54.4%), and concordant ER/PR-negative cases were high compared to other possibilities. Additionally, the study revealed that expression of Her2/neu was in contrast with the expression of ER and PR receptors. The findings of our study still support the importance of performing immunohistochemical stains for hormonal receptor classification in terms of better clinical outcomes and prognosis.
Literature
1.
go back to reference Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soer.CrossRef Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soer.CrossRef
2.
go back to reference Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22–34.PubMedCrossRef Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22–34.PubMedCrossRef
3.
5.
go back to reference Sree SV. Breast imaging: a survey. World J Clin Oncol. 2011;2(4):1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soer.CrossRef Sree SV. Breast imaging: a survey. World J Clin Oncol. 2011;2(4):1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soer.CrossRef
6.
go back to reference Saadaat R, Abdul-Ghafar J, Haidary AM, Rahmani S, Atta N. Age distribution and types of breast lesions among Afghan women diagnosed by fine needle aspiration cytology (FNAC) at a tertiary care centre in Afghanistan: a descriptive cross-sectional study. BMJ Open. 2020;10(9):1–5.CrossRef Saadaat R, Abdul-Ghafar J, Haidary AM, Rahmani S, Atta N. Age distribution and types of breast lesions among Afghan women diagnosed by fine needle aspiration cytology (FNAC) at a tertiary care centre in Afghanistan: a descriptive cross-sectional study. BMJ Open. 2020;10(9):1–5.CrossRef
8.
go back to reference Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Esmailnasab N, Babaee E. Breast cancer survival analysis based on immunohistochemistry subtypes (ER/PR/HER2): a retrospective cohort study. Arch Iran Med. 2016;19(10):680–6.PubMed Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Esmailnasab N, Babaee E. Breast cancer survival analysis based on immunohistochemistry subtypes (ER/PR/HER2): a retrospective cohort study. Arch Iran Med. 2016;19(10):680–6.PubMed
9.
go back to reference Mujtaba S, Haroon S, Faridi N, Rashid LF. Correlation of human epidermal growth factor receptor 2 (HER-2/neu) receptor status with hormone receptors Oestrogen Receptor, Progesterone Receptor status and other prognostic markers in breast cancer: An experience at tertiary care hospital in Karachi. J Pak Med Assoc. 2013;63(7):854–8.PubMed Mujtaba S, Haroon S, Faridi N, Rashid LF. Correlation of human epidermal growth factor receptor 2 (HER-2/neu) receptor status with hormone receptors Oestrogen Receptor, Progesterone Receptor status and other prognostic markers in breast cancer: An experience at tertiary care hospital in Karachi. J Pak Med Assoc. 2013;63(7):854–8.PubMed
10.
go back to reference DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.PubMedCrossRef DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.PubMedCrossRef
11.
go back to reference Gore CR, Gurwale S, Sammi A, Dey I, Deshpande AH. Estrogen, progesterone, and human epidermal growth factor receptor-2 in malignant breast lesions. Med J Dr DY Patil Vidyapeeth. 2018;11(1):9–15. Gore CR, Gurwale S, Sammi A, Dey I, Deshpande AH. Estrogen, progesterone, and human epidermal growth factor receptor-2 in malignant breast lesions. Med J Dr DY Patil Vidyapeeth. 2018;11(1):9–15.
12.
go back to reference Pourzand A, Fakhree MBA, Hashemzadeh S, Halimi M, Daryani A. Hormone receptor status in breast cancer and its relation to age and other prognostic factors. Breast Cancer Basic Clin Res. 2011;5(1):87–92. Pourzand A, Fakhree MBA, Hashemzadeh S, Halimi M, Daryani A. Hormone receptor status in breast cancer and its relation to age and other prognostic factors. Breast Cancer Basic Clin Res. 2011;5(1):87–92.
13.
14.
go back to reference Nakata T, Suzuki N. Chromogen-based immunohistochemical method for elucidation of the coexpression of two antigens using antibodies from the same species. J Histochem Cytochem. 2012;60(8):611–9.PubMedPubMedCentralCrossRef Nakata T, Suzuki N. Chromogen-based immunohistochemical method for elucidation of the coexpression of two antigens using antibodies from the same species. J Histochem Cytochem. 2012;60(8):611–9.PubMedPubMedCentralCrossRef
15.
go back to reference Longacre TA, Broaddus R, Chuang LT, Cohen MB, Jarboe EA, Mutter GL, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium. Arch Pathol Lab Med. 2017;141(11):1508–12.PubMedCrossRef Longacre TA, Broaddus R, Chuang LT, Cohen MB, Jarboe EA, Mutter GL, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium. Arch Pathol Lab Med. 2017;141(11):1508–12.PubMedCrossRef
16.
go back to reference Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.PubMedCrossRef Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.PubMedCrossRef
17.
go back to reference Almumen M. Immunohistochemical expression of VEGF in relation to other pathological parameters of breast carcinoma. J Cancer Ther. 2015;06(09):811–20.CrossRef Almumen M. Immunohistochemical expression of VEGF in relation to other pathological parameters of breast carcinoma. J Cancer Ther. 2015;06(09):811–20.CrossRef
18.
go back to reference Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: Reproducibility of grade and advantages of proliferation index. Mod Pathol. 2005;18(8):1067–78.PubMedCrossRef Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: Reproducibility of grade and advantages of proliferation index. Mod Pathol. 2005;18(8):1067–78.PubMedCrossRef
19.
go back to reference Roshed MM, Kamal S, Hossain SM, Akhtar S. Evaluation of breast cancer subtypes based on ER/PR and Her2 expression: a clinicopathologic study of hormone receptor status (ER/PR/HER2-neu) in breast cancer. Faridpur Med Coll J. 2020;14(1):8–12.CrossRef Roshed MM, Kamal S, Hossain SM, Akhtar S. Evaluation of breast cancer subtypes based on ER/PR and Her2 expression: a clinicopathologic study of hormone receptor status (ER/PR/HER2-neu) in breast cancer. Faridpur Med Coll J. 2020;14(1):8–12.CrossRef
20.
go back to reference Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al. HER2 overexpression and correlation with other significant clinicopathologic parameters in ivorian breast cancer women 11 medical and health sciences 1112 oncology and carcinogenesis. BMC Clin Pathol. 2019;19:1.PubMedPubMedCentralCrossRef Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al. HER2 overexpression and correlation with other significant clinicopathologic parameters in ivorian breast cancer women 11 medical and health sciences 1112 oncology and carcinogenesis. BMC Clin Pathol. 2019;19:1.PubMedPubMedCentralCrossRef
21.
go back to reference Sohail SK, Sarfraz R, Imran M, Kamran M, Qamar S. Estrogen and Progesterone Receptor Expression in Breast Carcinoma and Its Association With Clinicopathological Variables Among the Pakistani Population. Cureus. 2020;12(8):e9751. https://doi.org/10.7759/cureus.9751. Sohail SK, Sarfraz R, Imran M, Kamran M, Qamar S. Estrogen and Progesterone Receptor Expression in Breast Carcinoma and Its Association With Clinicopathological Variables Among the Pakistani Population. Cureus. 2020;12(8):e9751. https://​doi.​org/​10.​7759/​cureus.​9751.
22.
go back to reference Wolff MS, Weston A. Breast cancer risk and environmental exposures. Environ Health Perspect. 1997;105(SUPPL. 4):891–6.PubMedPubMedCentral Wolff MS, Weston A. Breast cancer risk and environmental exposures. Environ Health Perspect. 1997;105(SUPPL. 4):891–6.PubMedPubMedCentral
23.
go back to reference Bowen DJ, Poole SF, White M, Lyn R, Flores DA, Haile HG, et al. The role of stress in breast cancer incidence: risk factors, interventions, and directions for the future. Int J Environ Res Public Health. 2021;18(4):1–15.CrossRef Bowen DJ, Poole SF, White M, Lyn R, Flores DA, Haile HG, et al. The role of stress in breast cancer incidence: risk factors, interventions, and directions for the future. Int J Environ Res Public Health. 2021;18(4):1–15.CrossRef
24.
go back to reference Koval LE, Dionisio KL, Friedman KP, Isaacs KK, Rager JE. Environmental mixtures and breast cancer: identifying co-exposure patterns between understudied vs breast cancer-associated chemicals using chemical inventory informatics. J Expo Sci Environ Epidemiol. 2022;32(6):794–807.PubMedPubMedCentralCrossRef Koval LE, Dionisio KL, Friedman KP, Isaacs KK, Rager JE. Environmental mixtures and breast cancer: identifying co-exposure patterns between understudied vs breast cancer-associated chemicals using chemical inventory informatics. J Expo Sci Environ Epidemiol. 2022;32(6):794–807.PubMedPubMedCentralCrossRef
25.
go back to reference Ursin G, Bernstein L, Lord SJ, Karim R, Deapen D, Press MF, et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer. 2005;93(3):364–71.PubMedPubMedCentralCrossRef Ursin G, Bernstein L, Lord SJ, Karim R, Deapen D, Press MF, et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer. 2005;93(3):364–71.PubMedPubMedCentralCrossRef
26.
go back to reference Kelsey JL, Gammon MD, John EM. Reproductive factors and breast. Cancer. 1993;15(1):1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soer. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast. Cancer. 1993;15(1):1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soer.
28.
30.
go back to reference Bansal C, Sharma A, Pujani M, Pujani M, Sharma KL, Srivastava AN, et al. Correlation of hormone receptor and human epidermal growth factor Receptor-2/neu expression in breast cancer with various clinicopathologic factors. Indian J Med Paediatr Oncol. 2017;38(4):483–9.PubMedPubMedCentralCrossRef Bansal C, Sharma A, Pujani M, Pujani M, Sharma KL, Srivastava AN, et al. Correlation of hormone receptor and human epidermal growth factor Receptor-2/neu expression in breast cancer with various clinicopathologic factors. Indian J Med Paediatr Oncol. 2017;38(4):483–9.PubMedPubMedCentralCrossRef
31.
32.
go back to reference Hermansyah D, Pricilia G, Azrah A, Rahayu Y, Paramita DA, Siregar ES. Correlation between grading histopathology and sentinel lymph node metastasis in early breast cancer in university of sumatera utara hospital. Open Access Maced J Med Sci. 2021;9:679–82.CrossRef Hermansyah D, Pricilia G, Azrah A, Rahayu Y, Paramita DA, Siregar ES. Correlation between grading histopathology and sentinel lymph node metastasis in early breast cancer in university of sumatera utara hospital. Open Access Maced J Med Sci. 2021;9:679–82.CrossRef
33.
go back to reference Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Human Reprod Update. 2005;11:545–60.CrossRef Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Human Reprod Update. 2005;11:545–60.CrossRef
34.
go back to reference Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000;92(14):1126–35.PubMedCrossRef Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000;92(14):1126–35.PubMedCrossRef
35.
go back to reference Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J. 2009;15(6):593–602.PubMedCrossRef Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J. 2009;15(6):593–602.PubMedCrossRef
36.
go back to reference Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, et al. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. World J Surg Oncol. 2008;22:6. Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, et al. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. World J Surg Oncol. 2008;22:6.
37.
go back to reference Shaikh F, Jamal Q, Baig S, Hadi NI, Majeed N. Correlation of hormone receptor and HER-2/neu expression with clinicopathologic parameters in primary breast tumors. Asian Pacific J Cancer Prev. 2016;17(7):3363–7. Shaikh F, Jamal Q, Baig S, Hadi NI, Majeed N. Correlation of hormone receptor and HER-2/neu expression with clinicopathologic parameters in primary breast tumors. Asian Pacific J Cancer Prev. 2016;17(7):3363–7.
38.
go back to reference Yadav R, Sen R, Chauhan P. ER, PR, HER2/NEU status and relation to clinicopathological factors in breast carcinoma. Int J Pharm Pharm Sci. 2016;8(4):287–90. Yadav R, Sen R, Chauhan P. ER, PR, HER2/NEU status and relation to clinicopathological factors in breast carcinoma. Int J Pharm Pharm Sci. 2016;8(4):287–90.
41.
go back to reference Pajenga E, Rexha T, Çeliku S, Ugrinska A, Bejtja G. Hormonal receptor, human epidermal growth factor and its association with breast cancer tumor characteristics in Albania. Cent Eur J Public Health. 2016;24(3):171–5.PubMedCrossRef Pajenga E, Rexha T, Çeliku S, Ugrinska A, Bejtja G. Hormonal receptor, human epidermal growth factor and its association with breast cancer tumor characteristics in Albania. Cent Eur J Public Health. 2016;24(3):171–5.PubMedCrossRef
42.
go back to reference Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol. 2005;58(6):611–6.PubMedPubMedCentralCrossRef Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol. 2005;58(6):611–6.PubMedPubMedCentralCrossRef
43.
go back to reference Lakshmi A. A study of correlation of expression of ER, PR and HER2/neu receptor status with clinico-pathological parameters in breast carcinoma at a tertiary care centre. Int J Res Med Sci. 2015;1. Lakshmi A. A study of correlation of expression of ER, PR and HER2/neu receptor status with clinico-pathological parameters in breast carcinoma at a tertiary care centre. Int J Res Med Sci. 2015;1.
44.
go back to reference Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol. 2013;31(2):203–9.PubMedCrossRef Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol. 2013;31(2):203–9.PubMedCrossRef
45.
go back to reference Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21(10):1973–9.PubMedCrossRef Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21(10):1973–9.PubMedCrossRef
46.
go back to reference Article O, Yadav R, Sen R, Chauhan P. ER, PR, Her2/neu status and relation to clinicopathological factors in breast carcinoma. 2016. Article O, Yadav R, Sen R, Chauhan P. ER, PR, Her2/neu status and relation to clinicopathological factors in breast carcinoma. 2016.
47.
go back to reference Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247–69.PubMedCrossRef Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247–69.PubMedCrossRef
48.
go back to reference Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32.PubMedCrossRef Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32.PubMedCrossRef
49.
go back to reference Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–34.PubMedCrossRef Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–34.PubMedCrossRef
Metadata
Title
Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan
Authors
Esmatullah Esmat
Ahmed Maseh Haidary
Ramin Saadaat
Syeda Naghma Rizvi
Syeda Aleena
Mujtaba Haidari
Sayed Murtaza Sadat Hofiani
Nasrin Hussaini
Ahmadullah Hakimi
Abdullatif Khairy
Jamshid Abdul-Ghafar
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12129-5

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine